Q2 2024 EPS Estimates for DexCom, Inc. (NASDAQ:DXCM) Reduced by Leerink Partnrs

DexCom, Inc. (NASDAQ:DXCM) – Equities research analysts at Leerink Partnrs dropped their Q2 2024 earnings estimates for shares of DexCom in a report issued on Thursday, April 25th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will post earnings per share of $0.45 for the quarter, down from their prior estimate of $0.47. The consensus estimate for DexCom’s current full-year earnings is $1.78 per share. Leerink Partnrs also issued estimates for DexCom’s Q2 2025 earnings at $0.55 EPS, Q4 2025 earnings at $0.73 EPS, FY2025 earnings at $2.24 EPS and FY2028 earnings at $3.74 EPS.

A number of other equities analysts have also commented on DXCM. Royal Bank of Canada initiated coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. UBS Group increased their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Raymond James upped their target price on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday. Canaccord Genuity Group raised their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday. Finally, StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Tuesday, April 23rd. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $141.67.

DexCom Stock Down 9.9 %

DXCM opened at $124.34 on Monday. The firm’s 50-day simple moving average is $131.13 and its 200-day simple moving average is $118.81. DexCom has a twelve month low of $74.75 and a twelve month high of $142.00. The firm has a market cap of $49.24 billion, a price-to-earnings ratio of 80.22, a PEG ratio of 2.14 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.38% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Capital World Investors grew its holdings in shares of DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after acquiring an additional 5,256,092 shares in the last quarter. Norges Bank acquired a new position in DexCom during the fourth quarter valued at approximately $540,178,000. Artisan Partners Limited Partnership grew its stake in DexCom by 164.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares in the last quarter. Capital Research Global Investors increased its position in shares of DexCom by 21.4% during the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after purchasing an additional 2,695,296 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA acquired a new position in shares of DexCom during the 4th quarter worth approximately $231,773,000. Institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the transaction, the chief executive officer now owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the completion of the transaction, the chief operating officer now owns 273,913 shares of the company’s stock, valued at approximately $36,816,646.33. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the transaction, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The disclosure for this sale can be found here. In the last three months, insiders sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.